Related Experiment Video
Updated: Mar 7, 2026
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in
Ankur R Sangoi1, Malti Kshirsagar, Andres A Roma
1El Camino Hospital (A.R.S., M.K.), Mountain View UCSF (A.E.H., K.G., J.T.R., C.Z.), San Francisco Mills-Peninsula Hospital (M.C.), Burlingame UCSD (O.F.), San Diego Stanford University School of Medicine (A.K.F., T.L.), Stanford Cedars-Sinai Medical Center (J.R.), Los Angeles, CA Cleveland Clinic (A.A.R., J.K.M.), Cleveland, OH New York Presbyterian Hospital (L.H.E.) Memorial-Sloan Kettering Cancer Center (K.P., R.S.), New York, NY Emory University Hospital (K.H.), Atlanta, GA Clinical Pathology Associates (J.H.), Austin UT MD Anderson Cancer Center (A.Y.), Houston, TX Belfast Health and Social Care Trust (W.G.M.), Belfast, Northern Ireland, UK Brigham and Women's Hospital (M.R.N.) Massachusetts General Hospital (E.O.) Harvard Medical School/Beth Israel Deaconess Medical Center (A.H.B.), Boston, MA Yale School of Medicine (V.P.), New Haven, CT UAMS (C.M.Q.), Little Rock, AK Johns Hopkins Hospital (R.V.), Baltimore, MD.
Distinguishing osteosarcoma in gynecologic carcinosarcomas is challenging. The novel antibody SATB2 aids pathologists, improving diagnostic accuracy for osteosarcomatous components and guiding treatment decisions.
Area of Science:
- Gynecologic Pathology
- Surgical Pathology
- Oncology
Background:
- Distinguishing hyalinized stroma from true osteoid in gynecologic carcinosarcomas is diagnostically challenging.
- Accurate identification of heterologous osteosarcomatous components is crucial due to prognostic and therapeutic implications.
Purpose of the Study:
- To assess interobserver reproducibility among gynecologic pathologists in diagnosing osteosarcomatous components.
- To evaluate the utility of the novel antibody SATB2, a marker of osteoblastic differentiation, in identifying these components.
Main Methods:
- 22 gynecologic pathologists reviewed digital H&E images of 20 gynecologic tract carcinosarcomas.
- Cases included classic osteosarcoma (n=10) and osteosarcoma mimics (n=10).
- Interobserver agreement was assessed, and SATB2 expression was scored and compared with diagnoses.
Main Results:
- Moderate agreement (κ=0.483) was observed for morphologic diagnosis of osteosarcoma.
- SATB2 demonstrated 100% sensitivity and 60% specificity in differentiating true osteosarcoma from mimics.
- Negative SATB2 staining would have led 73% of reviewers to downgrade cases, reducing false positives.
Conclusions:
- Gynecologic pathologists show only moderate agreement in diagnosing heterologous osteosarcoma morphologically.
- Negative SATB2 staining can serve as a valuable surrogate marker to enhance diagnostic accuracy for osteosarcomatous components.
